RxDoctor Payments Data

Karli King, PA

Medical · Plainville, CTNPI 1477027175

Payments from drug & device makers

$2,055in general payments, 2019–2025

Across 45 payments — averaging $45.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$653
  • Corcept Therapeutics$342
  • AstraZeneca$289
  • Lilly USA, LLC$130
  • Kyowa Kirin, Inc.$125
  • Cequr Corporation$94
  • plus $421 from 9 others

What the payments were for

  • Food & beverage$2,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,055 in reported general payments places this provider in the 80th percentile of 592 medical providers in Connecticut.

See all medical providers in Connecticut

Medicare billing

Part B allowed, 2024
$25,302
Medicare patients
150
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide268$502,584
MounjaroTirzepatide233$313,512
TrulicityDulaglutide119$160,306
JardianceEmpagliflozin92$134,417
FarxigaDapagliflozin Propanediol94$131,152
Tresiba Flextouch U-100Insulin Degludec106$85,871
Tresiba Flextouch U-200Insulin Degludec65$85,344
Humalog Kwikpen U-200Insulin Lispro21$81,776
RybelsusSemaglutide27$61,933
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog35$58,817
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/746$51,821
Xigduo XrDapaglifloz Propaned/Metformin14$23,256
Lantus SolostarInsulin Glargine,hum.Rec.Anlog91$21,431
Repatha SureclickEvolocumab18$18,461
VascepaIcosapent Ethyl23$13,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$653$564,517295 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$130$486,716389 claims
AstraZenecaFarxiga$289$131,15294 claims
AbbVieSynthroid$16$7,61276 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 592 medical providers in Connecticut.

Other medical in Plainville

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →